No Data
No Data
We Think That There Are More Issues For GemPharmatech (SHSE:688046) Than Just Sluggish Earnings
YaoKang Biotech (688046.SH): Cumulative repurchase of 0.3712% of the company's shares.
On September 2nd, GeLongHui announced that as of August 31st, 2024, the company has repurchased a total of 1,521,975 shares of the company through the Shanghai Stock Exchange trading system through centralized competitive bidding, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest repurchase price was 19.17 yuan per share, and the lowest price was 11.89 yuan per share. The total amount paid was RMB 23,862,462.57 (excluding stamp duty, transaction fees, and other trading costs).
Yakkang Biotech 2024 Semi-Annual Report
Summary of Yakkang Biotech\'s 2024 Semi-Annual Report
Yao Kang Biology (688046.SH) released its semi-annual performance, with a net income of 76.34 million yuan, a year-on-year decrease of 1.59%.
Yao Kang Biology (688046.SH) disclosed the semi-annual report for 2024, and the company achieved revenue of 0.34 billion during the reporting period...
Pharmaron (688046.SH): The net income in the first half of the year was 76.3377 million yuan, a year-on-year decrease of 1.59%. It plans to distribute a dividend of 0.3 yuan per share.
On August 28, Gelonghui announced its interim report for the first half of 2024. During the reporting period, it achieved revenue of 0.34 billion yuan, a year-on-year increase of 15.05%. The net income attributable to shareholders of the listed company was 76.3377 million yuan, a year-on-year decrease of 1.59%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 58.4371 million yuan, a year-on-year increase of 10.73%. The basic earnings per share was 0.19 yuan. The company plans to distribute a cash dividend of 0.30 yuan (including tax) per 10 shares to all shareholders.
No Data
No Data